An investigator-developed drug has shown preclinical efficacy and is worth testing in clinical trials in aggressive breast ...

The companies will submit data showing zipalertinib resulted in a 35.2 percent response rate in patients with exon 20 mutations.

The FDA also approved Thermo Fisher's Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for Hyrnuo.

The firm will initially seek approval in patients who've had prior ALK inhibitors but has ambitions to eventually make neladalkib a first-line option.

"The CIRM grant will enable ReviR Therapeutics to further develop their preclinical candidate through rigorous preclinical studies and into clinical trials, with an initial goal to ensure that the ...

ProFound Therapeutics will use its proteomic technology and Quotient Therapeutics its genomics platform to uncover respiratory and liver disease treatments.